EP07.05. Neoadjuvant Chemotherapy or Chemo-IO in Resectable KRAS-Mutated Non-small Cell Lung Cancer (NSCLC) Patients: Single Center Experience - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Kaiwen Wang
Meta Tag
Speaker Kaiwen Wang
Topic Early-Stage NSCLC: Pushing the Boundaries
neoadjuvant chemotherapy
KRAS-mutated non-small cell lung cancer
major pathological response
pathological complete response
event-free survival
overall survival
STK11 co-mutation
TP53 co-mutation
KRAS G12C mutation
Powered By